Results 101 to 110 of about 147,037 (114)

Purification, Identification, and Properties of a Novel Carotenoid Produced by Arthrobacter sp. QL17 Isolated from Mount Qomolangma

Antioxidants, 2022
Gaosen Zhang, Yujie Wu, Xue Yu
exaly  

Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f® for ovarian stimulation: a phase-three trial

Reproductive BioMedicine Online, 2023
exaly  

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

Cancer Chemotherapy and Pharmacology, 2020
Guoping Yang, Can Guo
exaly  

UBE 2 QL 1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene

Human Mutation, 2013
Noel Clarke, Anne-Bine Skytte, Eamonn Maher   +2 more
exaly  

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

Frontiers in Pharmacology, 2020
Hong Zhang, Quan Liu, Wei Wei
exaly  

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration

Ophthalmology Retina
Miroslav Veith, Ignasi Jurgens, Agnieszka Nowosielska   +2 more
exaly  

Implementation of valid and stable algorithm of QL1-NMF for analyzing environmental elf magnetic signals

2017
Motoaki Mouri, Ichi Takumi, Hiroshi Yasukawa   +2 more
exaly  

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study

Journal of Hematology and Oncology
Yaxiong Zhang, Wenfeng Fang, Xiaoyan Kang   +2 more
exaly  

Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial

EClinicalMedicine
Zhunhao Zheng, Cihui Yan
exaly  

QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial

British Journal of Cancer
Jin Zhang, Zhonghua Wang, Zhimin Shao
exaly